表紙
市場調查報告書

癌症治療藥生物相似藥的全球市場:產業趨勢、市場佔有率、市場規模、成長率、市場機會、預測 2019年∼2024年

Oncology Biosimilars Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024

出版商 IMARC Services Private Limited 商品編碼 916397
出版日期 內容資訊 英文 102 Pages
商品交期: 2-3個工作天內
價格
Back to Top
癌症治療藥生物相似藥的全球市場:產業趨勢、市場佔有率、市場規模、成長率、市場機會、預測 2019年∼2024年 Oncology Biosimilars Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024
出版日期: 2019年10月20日內容資訊: 英文 102 Pages
簡介

全球癌症治療藥生物相似藥市場在2018年估算為4億800萬美元的規模,在2019年∼2024年間,預測將以57.6%的年複合成長率發展,到2024年成長到62億6,800萬美元。

本報告提供全球癌症治療藥生物相似藥市場調查,市場概要,各產品類型、癌症類型、通路、地區的市場規模的變化與預測,市場成長要素及課題分析,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 序文

第2章 範圍與方法

  • 調查目的
  • 相關利益者
  • 出處
  • 市場預測
    • Bottom-Up(由下而上)方法
    • Top-Down(由上而下)方法
  • 預測方法

第3章 摘要整理

第4章 簡介

  • 概要
  • 主要產業趨勢

第5章 全球癌症治療藥生物相似藥市場

  • 市場概況
  • 市場效能
  • 各藥品類型
  • 各癌症類型
  • 各流通管道
  • 各地區
  • 市場預測

第6章 全球癌症治療藥生物相似藥市場:各藥品類型

  • 單株抗體
  • 免疫調節藥物
  • 顆粒細胞增生因子(G-CSF)
  • 造血劑

第7章 全球癌症治療藥生物相似藥市場:各癌症類型

  • 肺癌症
  • 大腸癌症
  • 子宮頸癌
  • 乳癌
  • 肝癌症
  • 胃癌
  • 腦瘤

第8章 全球癌症治療藥生物相似藥市場:各銷售管道

  • 醫院藥局
  • 線上藥局
  • 零售藥局
  • 其他

第9章 全球癌症治療藥生物相似藥市場:各地區

  • 歐洲
  • 北美
  • 亞太地區
  • 中東、非洲
  • 南美

第10章 SWOT分析

  • 概要
  • 優勢
  • 弱點
  • 機會
  • 威脅

第11章 價值鏈分析

第12章 波特的五力分析

  • 買方議價能力
  • 供給企業談判力
  • 新加入業者的威脅
  • 替代品的威脅
  • 競爭企業間的敵對關係

第13章 價格分析

第14章 競爭情形

  • 市場結構
  • 主要企業
  • 主要企業的簡介
    • Biocon
    • Celltrion Inc.
    • Dr. Reddy's Laboratories
    • Intas Pharmaceuticals Ltd.
    • STADA Arzneimittel AG
    • Pfizer Inc.
    • Apotex Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Sandoz International GmbH
    • BIOCAD
    • Mylan
    • F Hoffmann-La Roche
目錄
Product Code: SR1019E75_Report

The global oncology biosimilars market was worth US$ 408 Million in 2018. Cancer is a lifestyle disease that occurs due to the abnormal growth of cells and may result in the formation of a tumor. At present, most of the effective cancer treatments are based on biological drugs, also known as biologics, and include targeted therapies as well as immunotherapies. These drugs are produced using living organisms, including bacteria, yeast, and animal or plant cells, and require complex manufacturing processes and long development time. As a result, the cost of these drugs is relatively higher, which adds to the expense of cancer treatment. To lower the price of treatment, the interest in the development of biosimilars of branded oncology biologics has been increasing. These biosimilars are highly similar to the reference biologics in terms of effectiveness and safety and can help in significantly reducing the expenditure on cancer treatment due to their lower cost.

Over the years, the rising number of geriatric population and environmental degradation have increased the prevalence of cancer across the globe. These factors, along with the inflating cost of cancer care, have increased the burden on healthcare systems worldwide. Consequently, governing authorities in numerous countries are promoting the uptake of biosimilars as a cost-containment measure. For instance, the United States Food and Drug Administration (USFDA) has developed information materials for physicians and patients to educate them about biosimilars. Apart from this, the availability of affordable medication has also been associated with earlier and wider therapy use as well as improved patient access. Besides this, oncology biosimilars can also increase industry competition, owing to which they have the potential to drive down the prices of biological drugs further. Some of the other growth-inducing factors for the market include approaching patent expiries of branded biologics and increasing research and development (R&D) activities by biosimilar manufacturers. Looking forward, IMARC Group expects the market to reach a value of US$ 6,268 Million by 2024, registering a CAGR of 57.6% during 2019-2024.

Report Coverage:

Historical, Current and Future Market Trends

Market Breakup by Drug Type:

  • Monoclonal Antibody
  • Immunomodulators
  • G-CSF
  • Hematopoietic Agents
  • Others

Market Breakup by Cancer Type:

  • Lung Cancer
  • Colorectal Cancer
  • Cervical Cancer
  • Breast Cancer
  • Kidney Cancer
  • Stomach Cancer
  • Brain Cancer
  • Others

Market Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
  • Others

Market Breakup by Region:

  • Europe
  • Asia Pacific
  • North America
  • Middle East and Africa
  • Latin America

Competitive Landscape

The report has also analyzed the competitive landscape of the market with some of the key players being Biocon, Celltrion Inc., Dr. Reddy's Laboratories, Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Pfizer Inc., Apotex Inc., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, BIOCAD, Mylan, F Hoffmann-La Roche, etc.

Key Questions Answered in This Report:

  • How has the global oncology biosimilars market performed so far and how will it perform in the coming years?
  • What are the key regional markets in the global oncology biosimilars industry?
  • What is the breakup of the market based on the drug type?
  • What is the breakup of the market based on the cancer type?
  • What is the breakup of the market based on the distribution channel?
  • What are the various stages in the value chain of the global oncology biosimilars industry?
  • What are the key driving factors and challenges in the global oncology biosimilars industry?
  • What is the structure of the global oncology biosimilars industry and who are the key players?
  • What is the degree of competition in the global oncology biosimilars industry?

Table of Contents

1. Preface

2. Scope and Methodology

  • 2.1. Objectives of the Study
  • 2.2. Stakeholders
  • 2.3. Data Sources
    • 2.3.1. Primary Sources
    • 2.3.2. Secondary Sources
  • 2.4. Market Estimation
    • 2.4.1. Bottom-Up Approach
    • 2.4.2. Top-Down Approach
  • 2.5. Forecasting Methodology

3. Executive Summary

4. Introduction

  • 4.1. Overview
  • 4.2. Key Industry Trends

5. Global Oncology Biosimilars Market

  • 5.1. Market Overview
  • 5.2. Market Performance
  • 5.3. Market Breakup by Drug Type
  • 5.4. Market Breakup by Cancer Type
  • 5.5. Market Breakup by Distribution Channel
  • 5.6. Market Breakup by Region
  • 5.7. Market Forecast

6. Market Breakup by Drug Type

  • 6.1. Monoclonal Antibody
    • 6.1.1. Market Trends
    • 6.1.2. Market Forecast
  • 6.2. Immunomodulators
    • 6.2.1. Market Trends
    • 6.2.2. Market Forecast
  • 6.3. G-CSF
    • 6.3.1. Market Trends
    • 6.3.2. Market Forecast
  • 6.4. Hematopoietic Agents
    • 6.4.1. Market Trends
    • 6.4.2. Market Forecast
  • 6.5. Others
    • 6.5.1. Market Trends
    • 6.5.2. Market Forecast

7. Market Breakup by Cancer Type

  • 7.1. Lung Cancer
    • 7.1.1. Market Trends
    • 7.1.2. Market Forecast
  • 7.2. Colorectal Cancer
    • 7.2.1. Market Trends
    • 7.2.2. Market Forecast
  • 7.3. Cervical Cancer
    • 7.3.1. Market Trends
    • 7.3.2. Market Forecast
  • 7.4. Breast Cancer
    • 7.4.1. Market Trends
    • 7.4.2. Market Forecast
  • 7.5. Kidney Cancer
    • 7.5.1. Market Trends
    • 7.5.2. Market Forecast
  • 7.6. Stomach Cancer
    • 7.6.1. Market Trends
    • 7.6.2. Market Forecast
  • 7.7. Brain Cancer
    • 7.7.1. Market Trends
    • 7.7.2. Market Forecast
  • 7.8. Others
    • 7.8.1. Market Trends
    • 7.8.2. Market Forecast

8. Market Breakup by Distribution Channel

  • 8.1. Hospital Pharmacies
    • 8.1.1. Market Trends
    • 8.1.2. Market Forecast
  • 8.2. Online Pharmacies
    • 8.2.1. Market Trends
    • 8.2.2. Market Forecast
  • 8.3. Retail Pharmacies
    • 8.3.1. Market Trends
    • 8.3.2. Market Forecast
  • 8.4. Others
    • 8.4.1. Market Trends
    • 8.4.2. Market Forecast

9. Market Breakup by Region

  • 9.1. Europe
    • 9.1.1. Market Trends
    • 9.1.2. Market Forecast
  • 9.2. Asia Pacific
    • 9.2.1. Market Trends
    • 9.2.2. Market Forecast
  • 9.3. North America
    • 9.3.1. Market Trends
    • 9.3.2. Market Forecast
  • 9.4. Middle East and Africa
    • 9.4.1. Market Trends
    • 9.4.2. Market Forecast
  • 9.5. Latin America
    • 9.5.1. Market Trends
    • 9.5.2. Market Forecast

10. SWOT Analysis

  • 10.1. Overview
  • 10.2. Strengths
  • 10.3. Weaknesses
  • 10.4. Opportunities
  • 10.5. Threats

11. Value Chain Analysis

12. Porters Five Forces Analysis

  • 12.1. Overview
  • 12.2. Bargaining Power of Buyers
  • 12.3. Bargaining Power of Suppliers
  • 12.4. Degree of Competition
  • 12.5. Threat of New Entrants
  • 12.6. Threat of Substitutes

13. Price Analysis

14. Competitive Landscape

  • 14.1. Market Structure
  • 14.2. Key Players
  • 14.3. Profiles of Key Players
    • 14.3.1. Biocon
    • 14.3.2. Celltrion Inc.
    • 14.3.3. Dr. Reddy's Laboratories
    • 14.3.4. Intas Pharmaceuticals Ltd.
    • 14.3.5. STADA Arzneimittel AG
    • 14.3.6. Pfizer Inc.
    • 14.3.7. Apotex Inc.
    • 14.3.8. Teva Pharmaceutical Industries Ltd.
    • 14.3.9. Sandoz International GmbH
    • 14.3.10. BIOCAD
    • 14.3.11. Mylan
    • 14.3.12. F Hoffmann-La Roche

List of Figures

  • Figure 1: Global: Oncology Biosimilars Market: Major Drivers and Challenges
  • Figure 2: Global: Oncology Biosimilars Market: Sales Value (in Billion US$), 2013-2018
  • Figure 3: Global: Oncology Biosimilars Market: Breakup by Drug Type (in %), 2018
  • Figure 4: Global: Oncology Biosimilars Market: Breakup by Cancer Type (in %), 2018
  • Figure 5: Global: Oncology Biosimilars Market: Breakup by Distribution Channel (in %), 2018
  • Figure 6: Global: Oncology Biosimilars Market: Breakup by Region (in %), 2018
  • Figure 7: Global: Oncology Biosimilars Market Forecast: Sales Value (in Billion US$), 2019-2024
  • Figure 8: Global: Oncology Biosimilars Industry: SWOT Analysis
  • Figure 9: Global: Oncology Biosimilars Industry: Value Chain Analysis
  • Figure 10: Global: Oncology Biosimilars Industry: Porter's Five Forces Analysis
  • Figure 11: Global: Oncology Biosimilars (Monoclonal Antibody) Market: Sales Value (in Million US$), 2013 & 2018
  • Figure 12: Global: Oncology Biosimilars (Monoclonal Antibody) Market Forecast: Sales Value (in Million US$), 2019-2024
  • Figure 13: Global: Oncology Biosimilars (Immunomodulators) Market: Sales Value (in Million US$), 2013 & 2018
  • Figure 14: Global: Oncology Biosimilars (Immunomodulators) Market Forecast: Sales Value (in Million US$), 2019-2024
  • Figure 15: Global: Oncology Biosimilars (G-CSF) Market: Sales Value (in Million US$), 2013 & 2018
  • Figure 16: Global: Oncology Biosimilars (G-CSF) Market Forecast: Sales Value (in Million US$), 2019-2024
  • Figure 17: Global: Oncology Biosimilars (Hematopoietic Agents) Market: Sales Value (in Million US$), 2013 & 2018
  • Figure 18: Global: Oncology Biosimilars (Hematopoietic Agents) Market Forecast: Sales Value (in Million US$), 2019-2024
  • Figure 19: Global: Oncology Biosimilars (Other Drug Types) Market: Sales Value (in Million US$), 2013 & 2018
  • Figure 20: Global: Oncology Biosimilars (Other Drug Types) Market Forecast: Sales Value (in Million US$), 2019-2024
  • Figure 21: Global: Oncology Biosimilars (Lung Cancer) Market: Sales Value (in Million US$), 2013 & 2018
  • Figure 22: Global: Oncology Biosimilars (Lung Cancer) Market Forecast: Sales Value (in Million US$), 2019-2024
  • Figure 23: Global: Oncology Biosimilars (Colorectal Cancer) Market: Sales Value (in Million US$), 2013 & 2018
  • Figure 24: Global: Oncology Biosimilars (Colorectal Cancer) Market Forecast: Sales Value (in Million US$), 2019-2024
  • Figure 25: Global: Oncology Biosimilars (Cervical Cancer) Market: Sales Value (in Million US$), 2013 & 2018
  • Figure 26: Global: Oncology Biosimilars (Cervical Cancer) Market Forecast: Sales Value (in Million US$), 2019-2024
  • Figure 27: Global: Oncology Biosimilars (Breast Cancer) Market: Sales Value (in Million US$), 2013 & 2018
  • Figure 28: Global: Oncology Biosimilars (Breast Cancer) Market Forecast: Sales Value (in Million US$), 2019-2024
  • Figure 29: Global: Oncology Biosimilars (Kidney Cancer) Market: Sales Value (in Million US$), 2013 & 2018
  • Figure 30: Global: Oncology Biosimilars (Kidney Cancer) Market Forecast: Sales Value (in Million US$), 2019-2024
  • Figure 31: Global: Oncology Biosimilars (Stomach Cancer) Market: Sales Value (in Million US$), 2013 & 2018
  • Figure 32: Global: Oncology Biosimilars (Stomach Cancer) Market Forecast: Sales Value (in Million US$), 2019-2024
  • Figure 33: Global: Oncology Biosimilars (Brain Cancer) Market: Sales Value (in Million US$), 2013 & 2018
  • Figure 34: Global: Oncology Biosimilars (Brain Cancer) Market Forecast: Sales Value (in Million US$), 2019-2024
  • Figure 35: Global: Oncology Biosimilars (Other Cancer Types) Market: Sales Value (in Million US$), 2013 & 2018
  • Figure 36: Global: Oncology Biosimilars (Other Cancer Types) Market Forecast: Sales Value (in Million US$), 2019-2024
  • Figure 37: Global: Oncology Biosimilars Market: Sales through Hospital Pharmacies (in Million US$), 2013 & 2018
  • Figure 38: Global: Oncology Biosimilars Market Forecast: Sales through Hospital Pharmacies (in Million US$), 2019-2024
  • Figure 39: Global: Oncology Biosimilars Market: Sales through Online Pharmacies (in Million US$), 2013 & 2018
  • Figure 40: Global: Oncology Biosimilars Market Forecast: Sales through Online Pharmacies (in Million US$), 2019-2024
  • Figure 41: Global: Oncology Biosimilars Market: Sales through Retail Pharmacies (in Million US$), 2013 & 2018
  • Figure 42: Global: Oncology Biosimilars Market Forecast: Sales through Retail Pharmacies (in Million US$), 2019-2024
  • Figure 43: Global: Oncology Biosimilars Market: Sales through Other Distribution Channels (in Million US$), 2013 & 2018
  • Figure 44: Global: Oncology Biosimilars Market Forecast: Sales through Other Distribution Channels (in Million US$), 2019-2024
  • Figure 45: Europe: Oncology Biosimilars Market: Sales Value (in Million US$), 2013 & 2018
  • Figure 46: Europe: Oncology Biosimilars Market Forecast: Sales Value (in Million US$), 2019-2024
  • Figure 47: Asia Pacific: Oncology Biosimilars Market: Sales Value (in Million US$), 2013 & 2018
  • Figure 48: Asia Pacific: Oncology Biosimilars Market Forecast: Sales Value (in Million US$), 2019-2024
  • Figure 49: North America: Oncology Biosimilars Market: Sales Value (in Million US$), 2013 & 2018
  • Figure 50: North America: Oncology Biosimilars Market Forecast: Sales Value (in Million US$), 2019-2024
  • Figure 51: Middle East and Africa: Oncology Biosimilars Market: Sales Value (in Million US$), 2013 & 2018
  • Figure 52: Middle East and Africa: Oncology Biosimilars Market Forecast: Sales Value (in Million US$), 2019-2024
  • Figure 53: Latin America: Oncology Biosimilars Market: Sales Value (in Million US$), 2013 & 2018
  • Figure 54: Latin America: Oncology Biosimilars Market Forecast: Sales Value (in Million US$), 2019-2024

List of Tables

  • Table 1: Global: Oncology Biosimilars Market: Key Industry Highlights, 2018 and 2024
  • Table 2: Global: Oncology Biosimilars Market Forecast: Breakup by Drug Type (in Million US$), 2019-2024
  • Table 3: Global: Oncology Biosimilars Market Forecast: Breakup by Cancer Type (in Million US$), 2019-2024
  • Table 4: Global: Oncology Biosimilars Market Forecast: Breakup by Distribution Channel (in Million US$), 2019-2024
  • Table 5: Global: Oncology Biosimilars Market Forecast: Breakup by Region (in Million US$), 2019-2024
  • Table 6: Global: Oncology Biosimilars Market Structure
  • Table 7: Global: Oncology Biosimilars Market: Key Players
Back to Top